^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    ZFHX3 mutation

    i
    Other names: ZFHX3, Zinc Finger Homeobox 3, AT-Binding Transcription Factor 1, Zinc Finger Homeodomain Protein, Zinc Finger Homeobox Protein, AT Motif-Binding Factor 1, ATBF1, ZFH-3, Alpha-Fetoprotein Enhancer Binding Protein, Alpha-Fetoprotein Enhancer-Binding Protein, Chromosome 16 Open Reading Frame 47, C16orf47, ZNF927, ATBT
    Entrez ID:
    463
    Related biomarkers:
    Mutation
    CNA
    4ms
    Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies. (PubMed, Cell)
    Cell line and patient-derived xenograft-based drug tests validated the specific therapeutic responses predicted by multi-omics subtyping. This study provides a valuable resource as well as insights to better understand SCLC biology and improve clinical practice.
    Journal
    |
    RB1 (RB Transcriptional Corepressor 1) • FAT1 (FAT atypical cadherin 1) • ZFHX3 (Zinc Finger Homeobox 3) • CASP10 (Caspase 10)
    |
    RB1 deletion • RB1 mutation • FAT1 mutation • RB deletion • ZFHX3 mutation
    over1year
    Genomic characterization of intracranial teratomas using whole genome sequencing. (PubMed, Front Oncol)
    Prognostic analysis showed that TP53 mutations might be associated with poor prognosis of intracranial teratomas patients. Our study revealed the genetic characteristics of intracranial teratoma which might be valuable for guiding future targeted therapies.
    Journal
    |
    TP53 (Tumor protein P53) • CARD11 (Caspase Recruitment Domain Family Member 11) • IL2 (Interleukin 2) • ZFHX3 (Zinc Finger Homeobox 3) • ARAF (A-Raf Proto-Oncogene) • CCND2 (Cyclin D2) • GATA1 (GATA Binding Protein 1) • PSMD1 (Proteasome 26S Subunit Non-ATPase 1) • SYNE1 (Spectrin Repeat Containing Nuclear Envelope Protein 1) • ZMYM3 (Zinc Finger MYM-Type Containing 3) • ATP6AP1 (ATPase H+ Transporting Accessory Protein 1) • SMC1A (Structural Maintenance Of Chromosomes 1A)
    |
    TP53 mutation • ZFHX3 mutation
    almost2years
    Genomic markers and response to chemotherapy in locally advanced gastric cancer patients (EACR 2022)
    Conclusion Despite the small case series, the prevalence of PIK3CA variants in non-responsive patients warrants further investigation, considering the emerging of new targeted therapies against mutant PIK3CA . In the era of personalized medicine a wide genomic characterization of chemo-naïve tissues from GC patients can help stratifying patients for more tailored treatment.
    Clinical • Tumor mutational burden • MSi-H Biomarker
    |
    TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • ARID1A (AT-rich interaction domain 1A) • RNF43 (Ring Finger Protein 43) • FGF3 (Fibroblast growth factor 3) • GNAS (GNAS Complex Locus) • ZFHX3 (Zinc Finger Homeobox 3)
    |
    TMB-H • PIK3CA mutation • ARID1A mutation • MYC amplification • RNF43 mutation • ZFHX3 mutation
    |
    TruSight Oncology 500 Assay
    2years
    Prognostic effect of coexisting TP53 and ZFHX3 mutations in non-small cell lung cancer patients treated with immune checkpoint inhibitors. (PubMed, Scand J Immunol)
    Coexisting TP53 and ZFHX3 mutations are independent prognostic factors for advanced-stage NSCLC patients undergoing ICI treatment. These findings could help identify patients harboring TP53 mutations that would benefit from ICI treatment.
    Journal • Checkpoint inhibition • Tumor Mutational Burden • PD(L)-1 Biomarker • IO biomarker
    |
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • ZFHX3 (Zinc Finger Homeobox 3)
    |
    TP53 mutation • TP53 wild-type • TP53 mutation + ZFHX3 mutation • ZFHX3 mutation